Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.13
AUXL's Cash to Debt is ranked lower than
53% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. AUXL: 0.13 )
AUXL' s 10-Year Cash to Debt Range
Min: 0.08   Max: 15218
Current: 0.13

0.08
15218
Equity to Asset 0.14
AUXL's Equity to Asset is ranked lower than
53% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. AUXL: 0.14 )
AUXL' s 10-Year Equity to Asset Range
Min: -2.27   Max: 0.68
Current: 0.14

-2.27
0.68
F-Score: 2
Z-Score: 0.55
M-Score: -2.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -27.33
AUXL's Operating margin (%) is ranked higher than
53% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. AUXL: -27.33 )
AUXL' s 10-Year Operating margin (%) Range
Min: -335.41   Max: 21.62
Current: -27.33

-335.41
21.62
Net-margin (%) -36.62
AUXL's Net-margin (%) is ranked higher than
53% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. AUXL: -36.62 )
AUXL' s 10-Year Net-margin (%) Range
Min: -327.31   Max: 21.74
Current: -36.62

-327.31
21.74
ROE (%) -68.63
AUXL's ROE (%) is ranked higher than
51% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. AUXL: -68.63 )
AUXL' s 10-Year ROE (%) Range
Min: -111.79   Max: 60.46
Current: -68.63

-111.79
60.46
ROA (%) -12.88
AUXL's ROA (%) is ranked higher than
56% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. AUXL: -12.88 )
AUXL' s 10-Year ROA (%) Range
Min: -1000.92   Max: 27.33
Current: -12.88

-1000.92
27.33
ROC (Joel Greenblatt) (%) -313.48
AUXL's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. AUXL: -313.48 )
AUXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2174.84   Max: 290.53
Current: -313.48

-2174.84
290.53
Revenue Growth (%) 22.10
AUXL's Revenue Growth (%) is ranked higher than
88% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. AUXL: 22.10 )
AUXL' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 28.7
Current: 22.1

0
28.7
EBITDA Growth (%) -36.80
AUXL's EBITDA Growth (%) is ranked higher than
51% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. AUXL: -36.80 )
AUXL' s 10-Year EBITDA Growth (%) Range
Min: -68.8   Max: 75
Current: -36.8

-68.8
75
EPS Growth (%) -30.00
AUXL's EPS Growth (%) is ranked higher than
56% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. AUXL: -30.00 )
AUXL' s 10-Year EPS Growth (%) Range
Min: -70.7   Max: 81.6
Current: -30

-70.7
81.6
» AUXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AUXL Guru Trades in Q4 2013

Paul Tudor Jones 32,000 sh (-18.99%)
Jim Simons 115,900 sh (-51.4%)
Steven Cohen 423,581 sh (-62.73%)
» More
Q1 2014

AUXL Guru Trades in Q1 2014

John Paulson 4,000,000 sh (New)
Jim Simons 125,895 sh (+8.62%)
Paul Tudor Jones 10,900 sh (-65.94%)
Steven Cohen 36,463 sh (-91.39%)
» More
Q2 2014

AUXL Guru Trades in Q2 2014

Louis Moore Bacon 150,000 sh (New)
John Paulson 4,000,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q3 2014

AUXL Guru Trades in Q3 2014

Mario Gabelli 10,900 sh (New)
John Paulson 4,000,000 sh (unchged)
Louis Moore Bacon 100,000 sh (-33.33%)
» More
» Details

Insider Trades

Latest Guru Trades with AUXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-09-30 New Buy$17.31 - $31.18 $ 33.4758%10900
John Paulson 2014-03-31 New Buy0.53%$19.99 - $32.005 $ 33.4727%4000000
George Soros 2011-12-31 Sold Out 0.06%$14.21 - $19.93 $ 33.47101%0
George Soros 2011-09-30 New Buy0.06%$13.95 - $20.84 $ 33.4795%250000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.50
AUXL's P/B is ranked higher than
53% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. AUXL: 10.50 )
AUXL' s 10-Year P/B Range
Min: 1.85   Max: 67.57
Current: 10.5

1.85
67.57
P/S 4.10
AUXL's P/S is ranked higher than
71% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. AUXL: 4.10 )
AUXL' s 10-Year P/S Range
Min: 0.45   Max: 15.15
Current: 4.1

0.45
15.15
EV-to-EBIT -19.83
AUXL's EV-to-EBIT is ranked lower than
52% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. AUXL: -19.83 )
AUXL' s 10-Year EV-to-EBIT Range
Min: -107.6   Max: 38.5
Current: -19.83

-107.6
38.5
Current Ratio 1.26
AUXL's Current Ratio is ranked higher than
54% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. AUXL: 1.26 )
AUXL' s 10-Year Current Ratio Range
Min: 0.99   Max: 5.85
Current: 1.26

0.99
5.85
Quick Ratio 0.99
AUXL's Quick Ratio is ranked higher than
56% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. AUXL: 0.99 )
AUXL' s 10-Year Quick Ratio Range
Min: 0.71   Max: 5.59
Current: 0.99

0.71
5.59

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.97
AUXL's Price/Median PS Value is ranked higher than
84% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. AUXL: 0.97 )
AUXL' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 2.9
Current: 0.97

0.15
2.9
Earnings Yield (Greenblatt) -5.00
AUXL's Earnings Yield (Greenblatt) is ranked higher than
56% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AUXL: -5.00 )
AUXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.6   Max: 30.9
Current: -5

2.6
30.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:FEJ.Germany,
Auxilium Pharmaceuticals, Inc., incorporated in the state of Delaware in July 1999. The Company is a specialty biopharmaceutical company which develops and markets products for specialist audiences. The Company now have a portfolio of 12 approved products, including one product with two indications. Among other products in the U.S., Auxilium markets Testim (testosterone gel) for the topical treatment of hypogonadism, TESTOPEL (testosterone pellets) a long-acting implantable testosterone replacement therapy ("TRT") product, STENDRA (avanafil), an oral erectile dysfunction ("ED") therapy, Edex (alprostadil for injection), an injectable treatment for ED, Osbon ErecAid, the leading vacuum device for aiding ED, XIAFLEX (collagenase clostridium histolyticum or "CCH") for the treatment of Peyronie's disease ("PD" or "Peyronie's") and XIAFLEX for the treatment of Dupuytren's contracture ("DC" or "Dupuytren's"). We also have programs in Phase 2 clinical development for the treatment of Frozen Shoulder syndrome and cellulite, Striant, a buccal TRT, XIAFLEX for the treatment of PD in men with a palpable plaque and a curvature deformity of thirty degrees or greater at the start of therapy which was launched in the U.S. in January 2014 and is the first and only FDA-approved non-surgical treatment for PD. Approximately 75% of the Company's product shipments are to only three wholesalers: Cardinal Health, Inc., McKesson Corporation and AmerisourceBergen Corporation. The Company faces competition from competitors in North America, Europe and elsewhere from pharmaceutical companies, specialty pharmaceutical companies and biotechnology firms, universities and other research institutions and government agencies that are developing and commercializing pharmaceutical products.
» More Articles for AUXL

Headlines

Articles On GuruFocus.com
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
Auxilium Pharmaceuticals Inc. (AUXL) CFO James E Fickenscher sells 4,000 Shares Sep 16 2009 
Auxilium Pharmaceuticals Inc. (AUXL) CFO James E Fickenscher sells 4,000 Shares Sep 10 2009 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 10 2009 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) May 08 2009 


More From Other Websites
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events Dec 16 2014
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 12 2014
Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC Dec 11 2014
Auxilium Announces Date for Special Meeting of Stockholders Dec 11 2014
Auxilium Announces Date for Special Meeting of Stockholders Dec 11 2014
Endo Registration Statement Relating to Pending Auxilium Acquisition Declared Effective by the SEC Dec 11 2014
Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed... Nov 20 2014
Auxilium Pharmaceuticals, Inc. Presents STENDRA Data At SMSNA Scientific Meeting Nov 20 2014
Auxilium Pharmaceuticals, Inc. Presents XIAFLEX For Peyronie's Disease Data At SMSNA Scientific... Nov 20 2014
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 20 2014
Auxilium Pharmaceuticals, Inc. Presents XIAFLEX For Peyronie's Disease Data At SMSNA Scientific... Nov 20 2014
Auxilium Pharmaceuticals, Inc. Presents STENDRA Data At SMSNA Scientific Meeting Nov 20 2014
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events Nov 19 2014
Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed... Nov 19 2014
Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed... Nov 19 2014
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Nov 18 2014
Avanir's AVP-825 Approval Could be Delayed (Revised) Nov 12 2014
AUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 12 2014
Zoetis (ZTS) Looks Good: Stock Gains 8.9% in Session Nov 12 2014
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss Nov 11 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK